BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burton AR, Maini MK. Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19. Immunol Rev 2021;299:108-17. [PMID: 33559128 DOI: 10.1111/imr.12953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Beretta M, Mouquet H. Advances in human monoclonal antibody therapy for HBV infection. Curr Opin Virol 2022;53:101205. [PMID: 35123237 DOI: 10.1016/j.coviro.2022.101205] [Reference Citation Analysis]
2 Shi Y. PLAN B for immunotherapy: Promoting and leveraging anti-tumor B cell immunity. J Control Release 2021;339:156-63. [PMID: 34563591 DOI: 10.1016/j.jconrel.2021.09.028] [Reference Citation Analysis]
3 Burton AR, Maini MK. Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19. Immunol Rev 2021;299:108-17. [PMID: 33559128 DOI: 10.1111/imr.12953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mauri C. Novel Frontiers in Regulatory B cells. Immunol Rev 2021;299:5-9. [PMID: 33686653 DOI: 10.1111/imr.12964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sachinidis A, Garyfallos A. Double Negative (DN) B cells: A connecting bridge between rheumatic diseases and COVID-19? Mediterr J Rheumatol 2021;32:192-9. [PMID: 34964023 DOI: 10.31138/mjr.32.3.192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]